Stock COV CLEO DIAGNOSTICS LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Cleo Diagnostics Ltd

Equities

COV

AU0000288045

Delayed Australian S.E.
Other stock markets
 10:11:52 2024-06-02 pm EDT 		5-day change 1st Jan Change
0.24 AUD -4.00% Intraday chart for Cleo Diagnostics Ltd +41.18% +37.14%
May. 29 Study Finds Cleo Diagnostics ' Blood Test Outperforms Clinical Benchmarks MT
Apr. 11 Cleo Diagnostics Taps Lindus Health to Manage US Ovarian Cancer Clinical Trials MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Study Finds Cleo Diagnostics ' Blood Test Outperforms Clinical Benchmarks
MT
Cleo Diagnostics Taps Lindus Health to Manage US Ovarian Cancer Clinical Trials
MT
CLEO Taps HcFocus for US Market Entry
MT
Cleo Diagnostics Concludes Design Transfer of Ovarian Cancer Detection Test Technology
MT
50,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 1-DEC-2023.
CI
162,500 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 30-NOV-2023.
CI
Cleo Diagnostics Confirms Efficacy of Ovarian Cancer Test from Validation Study; Shares Surge 21%
MT
50,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 4-NOV-2023.
CI
425,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 21-OCT-2023.
CI
75,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 19-OCT-2023.
CI
150,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 18-OCT-2023.
CI
100,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 13-OCT-2023.
CI
Cleo Diagnostics Advances Development of Cancer Test Kit
MT
CLEO Diagnostics’ Chief Scientific Officer Move to Full-Time Arrangement
MT
150,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 30-SEP-2023.
CI
125,000 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 21-SEP-2023.
CI
37,500 Ordinary Shares of Cleo Diagnostics Ltd are subject to a Lock-Up Agreement Ending on 19-SEP-2023.
CI
CLEO Diagnostics Secures US Patent for Ovarian Cancer Biomarker Testing
MT
Cleo Diagnostics Ltd has completed an IPO in the amount of AUD 12 million.
CI
Cleo Diagnostics Ltd has filed an IPO in the amount of AUD 12 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COV Stock
  4. News Cleo Diagnostics Ltd